A selective PAR4 antagonist (IC50 = 0.56 nM); selective for PAR4 over PAR1, PAR2, and a panel of purified proteases; inhibits platelet aggregation in vitro in human platelet-rich plasma (IC50 = 7.3 nM); decreases platelet aggregation ex vivo at a dose of 0.2-1 mg/kg; prevents vascular occlusion and reduces thrombus formation by 82% in cynomolgus monkeys
Size
5 mg
Concentration
n/a
Applications
n/a
Other Names
BMS986120 PAR-1 2 4 PAR4AP HEK-293 human embryonic kidney